NervGen Pharma Corp. (NGENF)
| Previous Close | 1.5300 |
| Open | 1.5200 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 1.4700 - 1.5600 |
| 52 Week Range | 1.1000 - 2.9900 |
| Volume | |
| Avg. Volume | 76,920 |
| Market Cap | 104.891M |
| Beta (5Y Monthly) | 1.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2800 |
| Earnings Date | May 13, 2024 - May 17, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NewsfileNervGen Engages Russo Partners LLC to Provide Public Relations Services
Vancouver, British Columbia--(Newsfile Corp. - April 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that it has engaged Russo Partners LLC ("Russo Partners"), a New York based full-service strategic communications firm to provide media and public relations and related services for the Company.Russo Partners was engaged for
NewsfileNervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates
Anticipated completion of enrollment of the chronic cohort in the Phase 1b/2a clinical trial in Q2 2024CA$23 million bought deal financing completed in March 2024 provides expected cash runway through Q3 2025 Fast Track designation granted by U.S. Food and Drug Administration (FDA) for NVG-291 in spinal cord injuryVancouver, British Columbia--(Newsfile Corp. - April 17, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) a clinical-stage biotech company dedicated to developing innovative so
NewsfileNervGen Completes $23 Million Bought Deal Financing
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.Vancouver, British Columbia--(Newsfile Corp. - March 28, 2024) - NervGen Pharma Corp. (TSXV: NGEN) ("NervGen" or the "Company") is pleased to announce the closing of its previously announced public offering (the "Offering") including the full exercise of the underwriters' over-allotment option for aggregate gross proceeds to the Company of C$23,011,788. The Offering was made pursuant to an underwri
